Zhao Ying, Yang Yuan-Yuan, Wang Yao-Xian, Yang Hui-Min, Wu Sheng-Xian
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
Zhongguo Zhong Yao Za Zhi. 2018 Aug;43(15):3211-3215. doi: 10.19540/j.cnki.cjcmm.20180521.001.
The post-marketing re-evaluation of traditional Chinese medicine (TCM) is a crucial stage for drug evaluation. Due to the particularity of TCM, it is necessary to re-evaluate the effectiveness of certain Chinese medicines by studying and collecting the studies on safety of long-term/extensive populations under actual clinical application, in order to verify the effectiveness of post-marketing TCM. However, there is an absence in technical specifications for relevant clinical trials on re-evaluation of effectiveness at present. As a consequence, the preliminary technical specifications were drafted in this article, focusing on several perspectives related to the re-evaluation of post-marketing clinical effectiveness of TCM, including ethical protection, research plan formulation, real-world research methods, randomized controlled trial methods, research methods of clinical pharmacological mechanism, sublimation method of TCM theory and so on. The objective of writing this article is to provide general methodological guidance for the re-evaluation of TCM post-marketing effectiveness, so that the process and results of post-marketing re-evaluation of TCM can be more scientific and reasonable.
中药上市后再评价是药物评价的关键阶段。由于中药的特殊性,有必要通过研究和收集实际临床应用中长期/广泛人群的安全性研究,对某些中药的有效性进行再评价,以验证中药上市后的有效性。然而,目前关于有效性再评价的相关临床试验技术规范尚缺。因此,本文起草了初步技术规范,重点围绕中药上市后临床有效性再评价的几个方面,包括伦理保护、研究方案制定、真实世界研究方法、随机对照试验方法、临床药理机制研究方法、中医理论升华方法等。撰写本文的目的是为中药上市后有效性再评价提供一般方法学指导,使中药上市后再评价的过程和结果更加科学合理。